Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer
Biomerica (NASDAQ: BMRA) has appointed Scott Madel as Chief Commercial Officer to accelerate the commercialization of inFoods® IBS. Madel brings over 20 years of experience in healthcare and diagnostics, most recently serving as President of Boston Heart Diagnostics. His track record includes leading successful organizational turnarounds and growing Genova Diagnostics to over $100 million in annual revenue.
In his new role, Madel will focus on strategic partnerships, payer strategy, achieving 3rd party reimbursement, and expanding provider engagement for inFoods® IBS. His appointment aims to drive revenue growth and market expansion for Biomerica's innovative gastroenterology solutions.
Biomerica (NASDAQ: BMRA) ha nominato Scott Madel Chief Commercial Officer per accelerare la commercializzazione di inFoods® IBS. Madel vanta oltre 20 anni di esperienza nel settore sanitario e diagnostico, avendo recentemente ricoperto il ruolo di Presidente di Boston Heart Diagnostics. Nel suo percorso professionale ha guidato con successo importanti ristrutturazioni aziendali e ha portato Genova Diagnostics a superare i 100 milioni di dollari di fatturato annuo.
Nel suo nuovo incarico, Madel si concentrerà su partnership strategiche, strategie di rimborso, ottenimento del rimborso da terze parti e sull'ampliamento del coinvolgimento dei fornitori per inFoods® IBS. La sua nomina ha l’obiettivo di stimolare la crescita dei ricavi e l’espansione del mercato per le innovative soluzioni gastroenterologiche di Biomerica.
Biomerica (NASDAQ: BMRA) ha nombrado a Scott Madel como Director Comercial para acelerar la comercialización de inFoods® IBS. Madel aporta más de 20 años de experiencia en el sector sanitario y diagnóstico, habiendo sido recientemente Presidente de Boston Heart Diagnostics. Su trayectoria incluye liderar exitosas reorganizaciones y hacer crecer Genova Diagnostics hasta superar los 100 millones de dólares en ingresos anuales.
En su nuevo cargo, Madel se centrará en asociaciones estratégicas, estrategias con pagadores, lograr reembolsos de terceros y ampliar la participación de proveedores para inFoods® IBS. Su nombramiento tiene como objetivo impulsar el crecimiento de ingresos y la expansión del mercado para las innovadoras soluciones gastroenterológicas de Biomerica.
Biomerica (NASDAQ: BMRA)는 inFoods® IBS의 상업화를 가속화하기 위해 Scott Madel을 최고 상업 책임자(Chief Commercial Officer)로 임명했습니다. Madel은 의료 및 진단 분야에서 20년 이상의 경력을 보유하고 있으며, 최근에는 Boston Heart Diagnostics의 사장으로 재직했습니다. 그는 성공적인 조직 개편을 이끌고 Genova Diagnostics를 연간 1억 달러 이상의 매출을 올리는 회사로 성장시킨 경력이 있습니다.
새 역할에서 Madel은 전략적 파트너십, 지불자 전략, 제3자 상환 달성, 그리고 inFoods® IBS에 대한 공급자 참여 확대에 집중할 예정입니다. 그의 임명은 Biomerica의 혁신적인 위장병학 솔루션의 매출 성장과 시장 확장을 추진하는 데 목적이 있습니다.
Biomerica (NASDAQ : BMRA) a nommé Scott Madel au poste de Chief Commercial Officer afin d’accélérer la commercialisation de inFoods® IBS. Madel apporte plus de 20 ans d’expérience dans le secteur de la santé et du diagnostic, ayant récemment occupé le poste de Président de Boston Heart Diagnostics. Son parcours inclut la conduite réussie de restructurations organisationnelles et le développement de Genova Diagnostics jusqu’à dépasser 100 millions de dollars de chiffre d'affaires annuel.
Dans ses nouvelles fonctions, Madel se concentrera sur les partenariats stratégiques, la stratégie des payeurs, l’obtention du remboursement tiers et l’expansion de l’engagement des prestataires pour inFoods® IBS. Sa nomination vise à stimuler la croissance des revenus et l’expansion du marché des solutions innovantes en gastroentérologie de Biomerica.
Biomerica (NASDAQ: BMRA) hat Scott Madel zum Chief Commercial Officer ernannt, um die Kommerzialisierung von inFoods® IBS zu beschleunigen. Madel bringt über 20 Jahre Erfahrung im Gesundheits- und Diagnostikbereich mit und war zuletzt Präsident von Boston Heart Diagnostics. Zu seinen Erfolgen zählt die erfolgreiche Umstrukturierung von Organisationen sowie der Ausbau von Genova Diagnostics auf über 100 Millionen US-Dollar Jahresumsatz.
In seiner neuen Rolle wird Madel sich auf strategische Partnerschaften, Erstattungsstrategien, die Erlangung von Drittanbieter-Erstattungen und die Erweiterung der Einbindung von Anbietern für inFoods® IBS konzentrieren. Seine Ernennung zielt darauf ab, das Umsatzwachstum und die Marktexpansion für Biomericas innovative gastroenterologische Lösungen voranzutreiben.
- Appointment of experienced executive with proven track record in revenue growth and commercialization
- New CCO has history of successful organizational turnarounds at Boston Heart Diagnostics and Genova Diagnostics
- Previous success in growing Genova to over $100M in annual revenue
- Extensive experience in payer strategies and global expansion across 45 countries
- None.
Insights
Strategic CCO hiring signals Biomerica's intensified commercialization push for inFoods IBS, leveraging Madel's proven revenue growth expertise in diagnostics.
Biomerica's appointment of Scott Madel as Chief Commercial Officer represents a significant strategic move to accelerate commercialization of their flagship product, inFoods® IBS. Madel brings impressive credentials with over 20 years of experience in diagnostic commercialization and a proven track record of revenue growth leadership. His previous accomplishments include successfully turning around Boston Heart Diagnostics and growing Genova Diagnostics to
This appointment addresses a critical need for Biomerica – effective commercialization strategy for inFoods® IBS. The company is clearly prioritizing four key commercial objectives: strategic partnerships, payer strategy development, achieving third-party reimbursement, and scaling provider engagement. These elements are essential for successful diagnostics commercialization and represent fundamental challenges in the medical diagnostics industry.
Madel's dual expertise in both laboratory operations and pharmaceutical sales positions him uniquely to navigate the complex diagnostics marketplace. His experience with personalized testing solutions at Boston Heart Diagnostics aligns particularly well with Biomerica's personalized approach to IBS management. His international experience expanding Genova across 45 countries suggests Biomerica is serious about global market potential for inFoods®.
This hire signals a transition from product development to commercial execution phase for Biomerica's inFoods® technology. For a small biomedical company, securing experienced commercial leadership with proven revenue growth capabilities represents a significant operational milestone and suggests confidence in the market potential of their technology.
- Brings 20+ years of revenue growth leadership in laboratory testing, clinical diagnostics and global expansion
- Led successful organizational turnarounds and growth strategies at both Boston Heart Diagnostics and Genova Diagnostics
- Extensive track record in commercializing advanced laboratory testing, driving growth and payer strategies
IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Scott Madel as Chief Commercial Officer.
Scott brings more than two decades of cross-functional expertise in healthcare, diagnostics, commercialization, and payor strategy. Most recently, he served as President of Boston Heart Diagnostics, where he led a successful organizational turnaround, introduced novel cardiovascular testing technologies across diverse payer channels, and significantly boosted revenue through personalized testing solutions.
Prior to Boston Heart, he served as CEO of BioHealth Diagnostics and CEO of Genova Diagnostics Europe after initially joining Genova as Vice President of Business Development. During his tenure, he helped grow Genova to over
Scott's early career experience includes frontline field sales roles at Novartis Pharmaceuticals and Merck, providing him exceptional insight into the full commercial lifecycle. He holds a Bachelor of Science in Medical Microbiology and Immunology from the University of Wisconsin–Madison, studied at King’s College London and is currently completing his MBA from Northeastern University.
In his new role, Scott will expand and accelerate commercialization and revenue growth for inFoods® IBS, by focusing on strategic partnerships, developing a robust payer strategy, achieving 3rd party payer reimbursement, and scaling domestic and global provider engagement and brand recognition.
“I’m excited to join Biomerica and champion the growth of inFoods® IBS,” said Mr. Madel. “This innovative solution has the potential to substantially improve the quality of life for millions of patients suffering from chronic GI conditions. I look forward to working alongside the team to bring this clinically proven breakthrough technology to practitioners and patients worldwide—delivering better outcomes, improving patient experience, and reducing the cost to treat this chronic condition.”
“Scott’s rich commercial experience, knowledge and deep industry relationships should dramatically increase revenues from inFoods® IBS across markets. We’re confident his strategic insights will drive our domestic launch and future international business,” said Zack Irani, CEO of Biomerica.
About inFoods® IBS
inFoods® IBS is a diagnostic-guided therapy that identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation. Using a simple finger-stick blood sample, the test enables physicians to recommend targeted dietary changes tailored to the patient’s immune response—offering a non-pharmaceutical, precision-based approach to symptom relief.
A multicenter, double-blinded placebo controlled clinical study on the inFoods® IBS test was published in the June issue of Gastroenterology, the top peer-reviewed GI journal. As the largest study of its kind, it demonstrated statistically significant outcomes:
59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA’s endpoint for abdominal pain reduction, compared to42.2% in the control group.- Among IBS-C patients,
67.1% of patients in the treatment group vs.35.8% in the control group. - Among IBS-M patients,
66% of patients in the treatment group vs.29.5% in the control group.
These results highlight inFoods® IBS as the only targeted therapy to demonstrate efficacy specifically in IBS-M patients, a subgroup historically underserved by existing treatments. The study was conducted at leading U.S. institutions including Cleveland Clinic, Mayo Clinic, University of Michigan, and Beth Israel Deaconess Medical Center.
For more information about inFoods® IBS, visit www.inFoodsibs.com.
inFoods IBS is a Laboratory Developed Test (LDT) used within a single laboratory that is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the expansion and sales growth of the Company’s inFoods® IBS test and other tests, FDA clearance or possible future clearance of the Company’s inFoods® IBS test and other products, timing of the commercial launch of the inFoods® IBS test, the efficacy of the inFoods product, possible future revenues from the sale of the inFoods® IBS test, growth in future revenues from the sale of the inFoods® IBS test, acceptance of the inFoods® IBS test by physicians and their patients, international regulatory approval and sales of the inFoods® IBS test, accuracy, efficacy and clinical trial results of the inFoods® IBS test, the rapidity of testing results, negotiations with clinical labs who would offer the inFoods® IBS test, the ability of a CLIA-certified, high-complexity lab to offer the inFoods® IBS test as a laboratory developed test (LDT), discussions with physicians and physician groups who could or would offer the inFoods Test to their patients, efficacy of the inFoods IBS test to improve IBS symptoms in patients, the company’s ability to manufacture the inFoods® IBS test as a commercial product and to increase manufacturing capacity to meet future product demands, any future FDA marketing authorization, the uniqueness of the Company’s inFoods® IBS test and other products, pricing of the Company’s inFoods® IBS test, future possible insurer reimbursement for the inFoods® IBS test, patent protection on the inFoods® IBS and the underlying technology of the test, or on any of the Company’s other products or technologies, and current or future competition for the inFoods® IBS test from other medical manufacturers or distributors. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company’s tests and products; regulatory approvals necessary prior to commercialization any of the Company’s products; availability of the Company’s test kits and other products; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; the Company’s ability to comply with current and future regulations in the countries where our products are made and sold and the Company’s ability to obtain patent protection on any aspects of its rapid test technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact:
Zack Irani-Cohen
949-645-2111
investors@biomerica.com
Source: Biomerica, Inc.
FAQ
Who is Scott Madel and what is his new role at Biomerica (BMRA)?
What are Scott Madel's main responsibilities at Biomerica (BMRA)?
What is Scott Madel's track record in the diagnostics industry?
How will Scott Madel's appointment impact Biomerica's (BMRA) business strategy?
